Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis

Inclusion Criteria: * Have provided written informed consent in accordance with institutional, local, and national guidelines * Are ≥18 years of age at the start of screening * Have been on in-center hemodialysis for ≥12 weeks at the start of screening * Are currently maintained on Epoetin at the start of screening * If sexually active and a female of childbearing potential, are willing to use highly effective method of birth control ≥4 weeks before study enrollment and through the study * If a female of childbearing potential, have a negative pregnancy test during screening Exclusion Criteria: * Are scheduled for a renal transplantation during study (Note: patients awaiting transplantation with no date scheduled may enroll.) * Have an active malignancy or malignancy treated within one year prior to the start of screening for curative or palliative intent (Note: patients with non-melanoma skin cancers may enroll.) * Have known intolerance to any ESA or PEGylated molecule * Have been exposed to any investigational agent during the four weeks prior to the start of screening or are anticipated to receive such agents during the study * Have any significant medical or psychiatric condition judged by the investigator to prevent informed consent or study compliance * Are pregnant or nursing